Royal Bank of Canada’s Nuvectis Pharma NVCT Stock Holding History

Royal Bank of Canada’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10K	Sell	535 -729	-58%	-$8.16K	﹤0.01%	6680
2026 Q1	$10K	Buy	1,264 +342	+37%	+$2.93K	﹤0.01%	6162
2025 Q4	$7K	Sell	922 -30,084	-97%	-$196K	﹤0.01%	6593
2025 Q3	$186K	Sell	31,006 -226	-0.7%	-$1.55K	﹤0.01%	5132
2025 Q2	$233K	Buy	+31,232	New	+$283K	﹤0.01%	5047
2024 Q2	–	Sell	-270	Closed	-$2K	–	7383
2024 Q1	$2K	Sell	270 -2,077	-88%	-$17.7K	﹤0.01%	6687
2023 Q4	$19K	Buy	2,347 +1,259	+116%	+$11.2K	﹤0.01%	6335
2023 Q3	$14K	Sell	1,088 -1,604	-60%	-$23.2K	﹤0.01%	6315
2023 Q2	$43K	Buy	+2,692	New	+$43K	﹤0.01%	5840
2022 Q4	–	Sell	-76	Closed	-$1K	–	7561
2022 Q3	$1K	Buy	+76	New	+$708	﹤0.01%	7230

Other funds holding NVCT

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Royal Bank of Canada's NVCT Position: Q2 2026 in Review

Royal Bank of Canada reduced its Nuvectis Pharma (NVCT) stake by 58% in Q2 2026, selling an estimated $8.16K and leaving 535 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #6680.

Royal Bank of Canada first reported a position in NVCT in Q3 2022 and has held it in 10 quarters since. The position peaked at $233K in Q2 2025. 82 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

Royal Bank of Canada held 535 shares of Nuvectis Pharma worth $10K as of Q2 2026.
Royal Bank of Canada sold 729 Nuvectis Pharma shares in Q2 2026, an estimated $8.16K.
Nuvectis Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6680 holding.
Royal Bank of Canada first reported a position in Nuvectis Pharma in Q3 2022 and has held it in 10 quarters since.
Royal Bank of Canada's Nuvectis Pharma position peaked at $233K in Q2 2025.
82 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.